Binghong Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Binghong Xiong has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Li Ma
Department of Emergency, The Third Hospital of Mianyang, Sichuan Mental Health Center Mianyang, Sichuan Province, 621000, China
7 shared publications- Yong Cheng
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, No 1Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, 400016, PR China
6 shared publications Wei Huang
Department of Anorectal Surgery, The Ninth Peole's Hospital of Chongqing, Chongqing, 400700, China
5 shared publicationsCaiquan Zhang
2 shared publicationsHuayou Luo
Department of Gastrointestinal Surgery, First Affiliated Hospital of Kunming Medical University, No. 1 School of Clinical Medicine, Kunming Medical University, No. 295 Xichang Road, Wuhua District, Kunming, Yunnan Province, 650031, China
2 shared publicationsJingshan Liu
Peking University Shougang Hospital
2 shared publications
Latest Publications
- 1 August 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (8) , 1483-1492
Efficiency of bursectomy in patients with resectable gastric cancer: An updated meta-analysis
- 1 August 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (8) , 1483-1492
Efficiency of bursectomy in patients with resectable gastric cancer: An updated meta-analysis
- 1 November 2016
- Published by Taylor & Francis in Growth Factors
- Vol. 34 (5-6) , 187-195
The efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials
A meta-analysis was performed to examine the efficiency and safety of trastuzumab in patients with advanced gastric and gastroesophageal cancer (AGC). By searching multiple databases from 1990 to March 2016, all randomized controlled trials (RCTs) which compared the effect of trastuzumab-combined chemotherapy (TC) versus chemotherapy alone (CT) in gastric cancer would be included. Five RCTs with a total of 875 patients were included. Trastuzumab can improve the overall survival (OS) rate, progression-free survival (PFS), one-year survival rate, two-year survival rate and overall response rate (ORR) of patients with AGC. There were no difference between the two arms in terms of grade 3/4 adverse effects, such as vomiting, nausea, neutropenia, thrombocytopaenia and anemia. Diarrhea increased in TC group. Trastuzumab can significantly improve the survival rate, PFS, ORR of patients with AGC. It is safe and feasible and can be tolerated. It needs further prospective multinational multicenter RCTs with large samples to define the clinical benefits of trastuzumab.
- 1 November 2016
- Published by Taylor & Francis in Growth Factors
- Vol. 34 (5-6) , 187-195
The efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials
A meta-analysis was performed to examine the efficiency and safety of trastuzumab in patients with advanced gastric and gastroesophageal cancer (AGC). By searching multiple databases from 1990 to March 2016, all randomized controlled trials (RCTs) which compared the effect of trastuzumab-combined chemotherapy (TC) versus chemotherapy alone (CT) in gastric cancer would be included. Five RCTs with a total of 875 patients were included. Trastuzumab can improve the overall survival (OS) rate, progression-free survival (PFS), one-year survival rate, two-year survival rate and overall response rate (ORR) of patients with AGC. There were no difference between the two arms in terms of grade 3/4 adverse effects, such as vomiting, nausea, neutropenia, thrombocytopaenia and anemia. Diarrhea increased in TC group. Trastuzumab can significantly improve the survival rate, PFS, ORR of patients with AGC. It is safe and feasible and can be tolerated. It needs further prospective multinational multicenter RCTs with large samples to define the clinical benefits of trastuzumab.
- 30 March 2015
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 12 (1) , 145-154
Robotic vs laparoscopic radical hysterectomy for cervical cancer: a meta‐analysis
Background: To evaluate whether the safety and efficacy of robotic radical hysterectomy (RRH) in patients with cervical cancer (CC) are equivalent to those of laparoscopic radical hysterectomy (LRH).Methods: The Pubmed, Embase, Cochrane Library, Ovid and Web of Science databases were searched. Studies documenting a comparison of RRH with LRH for CC were selected. Operative and recovery outcomes, common morbidity, and oncological parameters were evaluated.Results: Compared with LRH, RRH was associated with less blood loss and shorter hospital stay. There were no significant differences in operative time, complications, mortality, transfusion, conversions, number of retrieved lymph nodes, recurrence or disease‐free survival between the two groups.Conclusion: RRH for CC is safe and feasible and may be an alternative treatment for CC. More multicentre randomized controlled trials investigating the long‐term oncological outcomes are required to determine the advantages of RRH over LRH in CC. Copyright © 2015 John Wiley & Sons, Ltd.
- 30 March 2015
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 12 (1) , 145-154
Robotic vs laparoscopic radical hysterectomy for cervical cancer: a meta‐analysis
Background: To evaluate whether the safety and efficacy of robotic radical hysterectomy (RRH) in patients with cervical cancer (CC) are equivalent to those of laparoscopic radical hysterectomy (LRH).Methods: The Pubmed, Embase, Cochrane Library, Ovid and Web of Science databases were searched. Studies documenting a comparison of RRH with LRH for CC were selected. Operative and recovery outcomes, common morbidity, and oncological parameters were evaluated.Results: Compared with LRH, RRH was associated with less blood loss and shorter hospital stay. There were no significant differences in operative time, complications, mortality, transfusion, conversions, number of retrieved lymph nodes, recurrence or disease‐free survival between the two groups.Conclusion: RRH for CC is safe and feasible and may be an alternative treatment for CC. More multicentre randomized controlled trials investigating the long‐term oncological outcomes are required to determine the advantages of RRH over LRH in CC. Copyright © 2015 John Wiley & Sons, Ltd.
- 1 March 2015
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 19 (3) , 516-526
Robotic Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer: a Meta-analysis of Eight Studies
- 1 March 2015
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 19 (3) , 516-526
Robotic Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer: a Meta-analysis of Eight Studies
- 1 May 2014
- Published by Elsevier in Journal of Surgical Research
- Vol. 188 (2) , 404-414
Robotic versus laparoscopic total mesorectal excision for rectal cancer: a meta-analysis
- 1 May 2014
- Published by Elsevier in Journal of Surgical Research
- Vol. 188 (2) , 404-414
Robotic versus laparoscopic total mesorectal excision for rectal cancer: a meta-analysis
- Retracted
- 24 February 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (10) , 1321-1330
RETRACTED: Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: An updated meta-analysis of randomized controlled trials
- 24 February 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (10) , 1321-1330
RetractedRETRACTED: Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: An updated meta-analysis of randomized controlled trials
- 1 December 2012
- Published by Elsevier in Surgical Oncology
- Vol. 21 (4) , 274-280
Robotic versus laparoscopic gastrectomy for gastric cancer: A meta-analysis of short outcomes
- 1 December 2012
- Published by Elsevier in Surgical Oncology
- Vol. 21 (4) , 274-280
Robotic versus laparoscopic gastrectomy for gastric cancer: A meta-analysis of short outcomes
- 1 September 2012
- Published by SAGE Publications in Journal of Laparoendoscopic & Advanced Surgical Techniques
- Vol. 22 (7) , 674-684
Laparoscopic Versus Open Total Mesorectal Excision for Middle and Low Rectal Cancer: A Meta-analysis of Results of Randomized Controlled Trials
Background: Laparoscopic total mesorectal excision (LTME) for rectal cancer remains controversial. The aim of this meta-analysis of randomized controlled trials (RCTs) is to compare LTME and open total mesorectal excision (OTME) as the primary treatment for patients with middle and low rectal cancer with regard to short-term outcomes. Materials and Methods: Literature searches of electronic databases (PubMed, Embase, and the Cochrane Library) and manual searches up to October 30, 2011 were performed. Prospective randomized clinical trials were eligible if they included patients with middle and low rectal cancer treated by LTME versus OTME. Fixed and random effects models were used. Review Manager version 5.1 software was used for pooled estimates. Results: Four RCTs enrolling 624 participants (LTME group, 308 cases; OTME group, 316 cases) were included in the meta-analysis. LTME for rectal cancer was associated with a significantly longer operative time but significantly less intraoperative blood loss and earlier time to pass first flatus. We found no significant differences in the number of lymph nodes, overall morbidity, and perioperative mortality rates between the two groups. Time to resume liquid diet, time to resume normal diet, and length of hospital stay, although not significantly different between the two groups, did suggest a positive trend toward LTME. Conclusions: It may be concluded that LTME is a safe and effective alternative to OTME and is justifiable under the setting of clinical trials. Additional RCTs that compare LTME and OTME and investigate the long-term oncological outcomes of LTME are required to determine the advantages of LTME over OTME.
- 1 September 2012
- Published by SAGE Publications in Journal of Laparoendoscopic & Advanced Surgical Techniques
- Vol. 22 (7) , 674-684
Laparoscopic Versus Open Total Mesorectal Excision for Middle and Low Rectal Cancer: A Meta-analysis of Results of Randomized Controlled Trials
Background: Laparoscopic total mesorectal excision (LTME) for rectal cancer remains controversial. The aim of this meta-analysis of randomized controlled trials (RCTs) is to compare LTME and open total mesorectal excision (OTME) as the primary treatment for patients with middle and low rectal cancer with regard to short-term outcomes. Materials and Methods: Literature searches of electronic databases (PubMed, Embase, and the Cochrane Library) and manual searches up to October 30, 2011 were performed. Prospective randomized clinical trials were eligible if they included patients with middle and low rectal cancer treated by LTME versus OTME. Fixed and random effects models were used. Review Manager version 5.1 software was used for pooled estimates. Results: Four RCTs enrolling 624 participants (LTME group, 308 cases; OTME group, 316 cases) were included in the meta-analysis. LTME for rectal cancer was associated with a significantly longer operative time but significantly less intraoperative blood loss and earlier time to pass first flatus. We found no significant differences in the number of lymph nodes, overall morbidity, and perioperative mortality rates between the two groups. Time to resume liquid diet, time to resume normal diet, and length of hospital stay, although not significantly different between the two groups, did suggest a positive trend toward LTME. Conclusions: It may be concluded that LTME is a safe and effective alternative to OTME and is justifiable under the setting of clinical trials. Additional RCTs that compare LTME and OTME and investigate the long-term oncological outcomes of LTME are required to determine the advantages of LTME over OTME.